Revolution Medicine has wowed investors and analysts by announcing dazzling data from its Phase III RASolute 302 trial ...
HWK‑206 targets SEZ6 with a biparatopic antibody designed to enhance binding, receptor clustering and internalization. Whitehawk plans to submit an Investigational New Drug (IND) application for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results